Purpose: To investigate safety, tolerability, and pharmacokinetic properties of single and multiple doses of novel translocator protein 18 kDa antagonist ONO-2952 in healthy subjects.
INTRODUCTION
The translocator protein 18 kDa (TSPO), previously known as the peripheral benzodiazepine receptor and the mitochondrial benzodiazepine receptor, is a 5 transmembrane domain protein located on the outer mitochondrial membrane. It is expressed ubiquitously in peripheral tissues and in the glial and ependymal cells of the central nervous system. [1] [2] [3] TSPO binds several ligands, both synthetic and endogenous, with high affinity. 4, 5 It is the binding of TSPO to cholesterol (the metabolic precursor for steroid biosynthesis) that underpins its role in steroid production, during which TSPO transports cholesterol from intracellular stores into the mitochondria. 5, 6 The expression of TSPO within glial cells of the brain, such as astrocytes, microglia, and oligodendrocytes, 7, 8 suggests it may be associated with pathologic manifestations. Neurologic lesions, such as those caused by brain damage, neuroinflammation, or psychiatric disorders, can be characterized by upregulation of these cells. As such, increased levels of TSPO are often detected in psychologic or neurologic disorders and imaging of TSPO via radioligands has been developed as a diagnostic tool. 3 In peripheral tissues, increased expression levels of TSPO are observed in cells associated with various cancerous tumor types, inflammation, and cardiovascular disease. 9 Neurosteroidogenesis, the production of steroids within the nervous system, is a mechanism by which TSPO may have a functional role in disease processes. Neurosteroids alter the balance of excitatory and inhibitory neurotransmission by modulating neuronal excitability via ion channels and other cell surface receptors. 10, 11 The transport of cholesterol across the mitochondrial membrane is rate-limiting in this process; thus, TSPO activity can regulate neurosteroid production and the binding of TSPO ligands has been shown to stimulate neurosteroidogenesis. 2, 12 Therefore, modifying the activity of TSPO may have implications for pharmacologic intervention in many diseases.
ONO-2952 is a novel and selective TSPO antagonist that binds with high affinity to TSPO in mitochondrial tissue preparations in vitro. 13 Antagonism of TSPO by ONO-2952 has been shown to inhibit restraint stress-induced production of the neurosteroid precursor pregnenolone in the hippocampus and noradrenaline release in the amygdala in rats, and thus has the possibility of normalizing the balance of excitatory and inhibitory neurotransmission. 13 Furthermore, ONO-2952 has been shown to attenuate bowel dysfunction in a rat restraint stress model as well as stress-induced defecation and freezing behavior in a rat conditioned fear stress model. 13 The antagonistic mode of action of ONO-2952 at TSPO provides a potentially novel pharmacologic intervention that may have therapeutic potential in many conditions due to overexpression of TSPO in many disease states. 14 The present Phase I studies were designed to investigate the safety, tolerability, and pharmacokinetic properties of ONO-2952 in healthy volunteers following the administration of single and multiple daily doses.
METHODS Subjects
Male and female subjects aged 18 to 55 years inclusive, with a body mass index of 19 to 35 inclusive, were eligible for inclusion. All subjects were considered healthy, as determined by medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory tests. All subjects provided written informed consent.
Women were surgically sterile, postmenopausal, or if of child-bearing potential they agreed to use doublebarrier method contraception for the duration of study.
Key exclusion criteria included a history or presence of any clinically significant psychiatric disease or disorder, a history or presence of any cardiovascular or gastrointestinal disorder, and any clinically significant drug or food allergy. Subjects were also excluded if they had used nicotine or any investigational medication within 6 months, prescription drugs within 14 days, nonprescription drugs within 7 days, or consumed alcohol or caffeine within 48 hours before dosing.
Declaration of Helsinki. The protocols were submitted for ethical review and approval was obtained in writing from the investigational site's institutional review board (IntegReview Ethical Review Board, Austin, Texas).
SAD Study
The SAD study consisted of 3 periods: screening (Day -22 to -2), dosing and evaluation (Day -1 to 4) during which patients were admitted to the investigational site, and follow-up for a maximum of 1 week after dosing (Day 5-8). Forty-eight subjects were enrolled in 6 cohorts of 8 subjects, randomized in a 3:1 ratio (ONO-2952:placebo). A single dose of ONO-2952 (3, 10, 30, 100, 200 , and 400 mg) or placebo was administered following an overnight fast. In food effect cohorts, (10 and 200 mg), subjects underwent an 11-day washout period before receiving an additional dose of ONO-2952 under fed conditions (dosing took place 30 minutes after the start of a high-fat, high-calorie breakfast consistent with US Food and Drug Administration guidelines in that approximately 50% of total energy content of the meal was derived from fat). Blood and urine samples were collected to characterize the pharmacokinetic profile of ONO-2952. Blood samples were collected predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours postdose in all subjects. Blood samples were processed to plasma and were stored at -701C or below. Urine samples from subjects receiving ONO-2952 3 and 400 mg were collected predose and at the following intervals postdose: 0 to 12, 12 to 24, 24 to 36, 36 to 48, 48 to 60, and 60 to 72 hours. Urine samples were stored at -701C or below.
MAD Study
The MAD study consisted of 3 periods: screening (Day -22 to -2), dosing, and evaluation (Day -1 to 24) during which patients were admitted to the investigational site, and follow-up for a maximum of 2 weeks after the last dose (Day 25-36). Thirty-six subjects were enrolled in 3 cohorts of 12 subjects, randomized in a 3:1 ratio (ONO-2952:placebo). ONO-2952 30, 60, or 100 mg or placebo was administered once daily for 21 days under fed conditions (dosing took place 30 minutes after the start of a standard breakfast based on the Step 2 American Heart Association Diet offering daily nutrition of approximately 30% fat, 55% carbohydrate, and 15% protein). Blood samples were collected predose on Days 1, 2, 4, 7, 10, 12, 14, 16, 18, and 21; and 0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours postdose on Days 1 and 21, with additional samples taken at 24, 36, 48, and 72 hours postdose on Day 21. Blood samples were processed to plasma and stored at -701C or below.
Safety Analysis
For both studies, adverse events were monitored and recorded from the time of administration of the study drug until the end of study and coded using MedDRA (Medical Dictionary for Regulatory Activities) (MSSO, U.S.A) version 14.1. Subjects underwent assessment of clinical laboratory evaluations, 12-lead ECG and vital signs, including blood pressure, pulse rate, respiratory rate, and body temperature at regular intervals throughout both studies. Psychiatric effects were assessed in the MAD study using the Personal Health Questionnaire Depression Scale, Generalized Anxiety Disorder 7-Item Scale, and Columbia-Suicide Severity Rating Scale.
Bioanalysis

SAD Study
Plasma and urine ONO-2952 concentrations were determined using a validated HPLC-MS method with quantitative range of 5 pg/mL to 10 ng/mL and 1 to 1000 ng/mL, respectively. Plasma samples were diluted using a range of dilution factors up to 1000fold to allow quantification in the range of 5 pg/mL to 10 ng/mL. In addition, dilution reproducibility at 1000-fold was confirmed as part of the assay validation. An internal standard, deuterated form of ONO-2952 was added to all plasma samples; analytes were isolated through solid-phase extraction and eluted with formic acid/methanol (1:50, v/v) using Oasis HLB (60 mg/3 cc) and Oasis MCX (Waters, USA) (60 mg/3 cc) cartridges. The eluate was evaporated under a nitrogen stream and the remaining residue was reconstituted with 5 mmol/L ammonium formate/ acetonitrile (1:1, v/v) and injected into an HPLC-MS (AB Sciex (SCIEX, USA) API 5000). An Inertsil ODS-4 (GL Sciences, Japan) column (2.1 mm internal diameter (I.D.) Â 100 mm; particle size, 2 μm) was used as the analytical column, and 5 mmol/L ammonium formate and acetonitrile were used as the mobile phases. The positive ion detection mode was used, and the concentrations of ONO-2952 and the internal standard were determined by the multiple reaction monitoring method (ONO-2952, m/z 399m/z 340; internal standard, m/z 404m/z 343). Incurred sample reanalysis was performed to verify the reliability of obtained plasma concentrations and the results of incurred sample reanalysis showed that the assay variability was within Ϯ20% in all reanalyzed samples, which met the quality control standards.
A urine sample was added with acetonitrile and internal standard, and diluted with 5 mmol/L ammonium formate/acetonitrile (1:1, v/v). The resulting sample was injected into a high-performance LC-MS. A Unison UK-C18 (Imtakt, USA) column (2 mm I.D. Â 50 mm; particle size, 3 μm) was used as the analytical column, and 5 mmol/L ammonium formate and acetonitrile were used as the mobile phases. The positive ion detection mode was used, and the concentrations of ONO-2952 and the internal standard were determined by the same multiple reaction monitoring method used for the plasma samples.
MAD Study
Plasma ONO-2952 concentrations were determined using a cross-validated LC-MS method with quantitative range of 0.5 to 1000 ng/mL. The quantitative range was refined following information about human exposure to ONO-2952 from the SAD study. Plasma samples were added with internal standard; analytes were isolated through solid-phase extraction using Oasis HLB (10 mg/ 96 well) and eluted with acetonitrile. The eluate was evaporated under a nitrogen stream. The remaining residue was reconstituted with 5 mmol/L ammonium formate/acetonitrile (4:6, v/v) and injected into the LC-MS system. The subsequent analytical procedures were as described for the single ascending dose study. A Cadenza CD-C18 (Imtakt, USA) column (2 mm I.D. Â 100 mm; particle size, 3 μm) was used as the analytical column, and 5 mmol/L ammonium formate / acetonitrile (4:6, v/v) was used as the mobile phases. The positive ion detection mode was used, and the concentrations of ONO-2952 and the internal standard were determined by the same multiple reaction monitoring method used for the samples collected in the SAD study.
Pharmacokinetic Profile
The pharmacokinetic parameters of ONO-2952 were calculated by a noncompartmental model using Phoenix WinNonlin version 6.1 (Certara, St Louis, Missouri).
SAD Study
C max , T max , and AUC last were calculated from plasma concentrations of ONO-2952. At all doses, the AUC last represented less than 80% of AUC 1 in most subjects. Hence, parameters dependent on estimation of the terminal elimination rate constant (lambda z) such as t ½ , CL/F, and V d /F were not reported.
MAD Study
C max , T max , AUC 0-24 ), and t ½ were calculated from plasma concentrations of ONO-2952. The accumulation ratios of AUC 24 between Day 1 and Day 21 were also calculated.
Statistical Analysis
Statistical analyses were performed using Statistical Analysis Software version 9.1.3 or 9.2 (SAS Institute Inc, Cary, North Carolina). Study populations analyzed were the Safety Set, all enrolled subjects who received study medication, and the Pharmacokinetic Evaluable Set, all enrolled subjects who received ONO-2952 and provided sufficient samples for pharmacokinetic evaluations. All safety data and pharmacokinetic parameters were summarized by treatment group using descriptive statistics. Statistical testing was performed 2-sided at the α¼ 0.05 level.
SAD Study
Dose proportionality of C max and AUC last was evaluated using the power model. 14 The point estimate of the intercept (ln[α]) and slope (β) with 90% CI was calculated by linear regression according to the least squares method. Food effect on C max , AUC last , and T max was evaluated at ONO-2952 10 and 200 mg. Natural-log transformed C max and AUC last were analyzed using a mixed ANOVA model. The geometric mean ratios and 90% CIs were determined. For T max , a 2-tailed Wilcoxon signed-rank test was used and the resulting P value presented.
MAD Study
Dose proportionality of C max and AUC 24 was evaluated after Day 21 using the same power model. The point estimate of the intercept and slope with 90% CIs were calculated by linear regression, as described above. The accumulation ratios were calculated as RAUC 24 (AUC 24hDay 21 /AUC 24hDay 1 ) and RC max (C maxDay21 /C maxDay1 ) (R is the accumulation factor; ratio of drug concentration observed during the dosing interval at steady-state (here this is Day 21) divided by drug concentration seen during the dosing interval after a single (first) dose (here this is Day 1)). The geometric mean and 95% CI of these ratios were calculated as follows: the mean of natural log-transformed values of the ratios and their 95% CI were calculated and the values obtained were exponentially back-transformed to the original scale. The accumulation ratios of subjects whose pharmacokinetic parameters on the first or last dosing day were judged not to be appropriately evaluated were not used for the calculation of the geometric mean ratios and 95% CI.
RESULTS
Subject Disposition and Demographic Characteristics SAD Study
A total of 48 subjects were enrolled: 36 subjects received ONO-2952 and 12 subjects received placebo. All subjects completed the study (Figure 1 ).
MAD Study
Thirty-six subjects were enrolled: 27 subjects received ONO-2952 and 9 received placebo. Three subjects did not complete the study: 2 subjects were discontinued from the study at the investigator's discretion because of adverse events (ONO-2952 30 mg: ventricular tachycardia; ONO-2952 100 mg: musculoskeletal chest pain and asthenia), the third subject (ONO-2952 60 mg) was lost to follow-up ( Figure 2) . Demographic characteristics of subjects for both studies are presented in Table I .
Safety
SAD Study
The overall incidence of adverse events experienced was low and ranged from 0% to 33% of subjects after a single dose of ONO-2952: 7 subjects experienced 11 adverse events (Table II) . Two subjects experienced headache and 2 subjects presyncope. All other adverse events were reported by 1 subject each. Adverse events judged possibly related to study drug were headache (n ¼ 2), diarrhea (n ¼ 1), and involuntary muscle contractions (n ¼ 1). All adverse events were mild, with the exception of 1 episode of presyncope, which was classed as moderate and considered unrelated to ONO-2952. All adverse events resolved without intervention. No treatment, dose, or food-related trends were observed in the incidence of adverse events, clinical laboratory results, vital sign measurements, or 12-lead ECG readings.
MAD Study
Twelve subjects experienced 27 adverse events (placebo, n ¼ 2; ONO-2952 30 mg, n ¼ 3; 60 mg, n ¼ 4; and 100 mg, n ¼ 3) (Table III) . Constipation and headache were the most frequent adverse events, experienced by 3 subjects each. Nineteen adverse events were judged possibly related to study drug, including constipation, diarrhea, nausea, salivary hypersecretion, dizziness, headache, abnormal dream, sleep disorder, and cold sweat. Two subjects were withdrawn from the study at the Investigator's discretion because of adverse events (ONO-2952 30 mg: ventricular tachycardia; ONO-2952 100 mg: musculoskeletal chest pain and asthenia), although these adverse events were judged to be unrelated to the study drug.
All adverse events resolved without intervention, with the exception of 1 subject who experienced mild constipation in the ONO-2952 60 mg cohort who was lost to follow-up and so the final status of the adverse event remains unknown. No treatment or food-related trends were observed in the incidence of adverse events, clinical laboratory results, vital sign measurements, 12-lead ECG readings, or psychiatric assessments.
Pharmacokinetic Profile SAD Study
After a single dose, ONO-2952 was absorbed and reached C max between 2.5 and 3.5 hours postdose in all cohorts under both fasted and fed conditions based on median T max values, declining slowly over the 72hour sampling period (see Figure 3 and Table IV) . Predose concentrations of ONO-2952 were o5% of C max in all subjects in the fed condition (ie, the second treatment period); therefore, no adjustment was made in the analysis between fasted and fed conditions. C max increased in a less than dose-proportional manner over the dose ranges analyzed with the point estimates of β (Figure 4) . Administration of ONO-2952 in the fed condition resulted in a statistically significant increase in C max and AUC last compared with fasted conditions (Figure 3) . Statistical analysis of the effect of dosing in the fed condition is presented in Table V . For C max , the ratios of geometric means at ONO-2952 10 mg and 200 mg were 229% (90% CI, 176-299) and 778% (90% CI, 623-971), respectively. For AUC last , the ratios of geometric means at ONO-2952 10 mg and 200 mg were 159% (90% CI, 131-192) and 382% (90% CI, 288-506), respectively. The differences in T max between fed and fasted conditions did not reach statistical significance (P 4 0.05). Urine ONO-2952 concentrations were below the limit of quantification in all samples evaluated and no urine pharmacokinetic parameters were calculated.
MAD Study
After multiple doses in the fed condition, median maximum plasma concentrations of ONO-2952 were observed at 3.0 to 4.0 hours postdose for all cohorts, and mean t ½ values were 37 to 42 hours (see Figure 5 and Table VI ). The pharmacokinetic profile of ONO-2952 reached steady state for each dose by Day 10 based on trough concentrations ( Figure 6) . C max and AUC 24 values on Day 21 from 30 to 100 mg increased in a slightly greater than dose-proportional manner (see Figure 7 and Table VI ). The point estimates of β for C max and AUC 24 over the range of ONO 2952 30 mg to 100 mg were 1.16 (90% CI, 0.98-1.35) and 1.20 (90% CI, 0.99-1.41), respectively. After oncedaily administration of ONO-2952 30, 60, and 100 mg for 21 days, geometric mean accumulation ratios of AUC 24 were 2.50 (95% CI, 2.09-2.98), 2.23 (95% CI, 1.85-2.68), and 2.73 (95% CI, 2.10-3.55), respectively, and those of C max were 1.65 (95% CI, 1.43-1.90), 1.56 (95% CI, 1.31-1.85), and 1.85 (95% CI, 1.38-2.49), respectively.
DISCUSSION
These studies investigated the safety, tolerability, and pharmacokinetic profile of ONO-2952 in healthy subjects following both single and multiple oral doses. Results from these studies demonstrate that ONO-2952 was well tolerated with no significant safety concerns after single doses up to 400 mg in fasted conditions and up to 200 mg in fed conditions; and during daily doses up to 100 mg over 21 days. No serious adverse events were reported during the studies, and no dose relationship was observed in the incidence of adverse events or other safety assessments.
In the SAD study, pharmacokinetic data indicated that under fasted conditions increases in exposure to ONO-2952 over the dose range tested were generally less than dose proportional. Administration of ONO-2952 under fed conditions increased the rate of absorption of ONO-2952 and resulted in a statistically significant increase in C max and AUC last compared with fasted conditions. The increased absorption of ONO-2952 in the fed state supports administration with food in future clinical trials. ONO-2952 demonstrated a relatively slow rate of elimination following single dosing. This resulted in the extrapolated portion of AUC 1 being 420% in most subjects. Therefore, it was not possible to calculate accurately the terminal elimination rate constant (lambda z) and several associated pharmacokinetic parameters (AUC 1 , CL/F, t ½ , and V d /F) could not be calculated reliably in this study.
In the MAD study, pharmacokinetic data indicated that under fed conditions exposure to ONO-2952 increased with dose; however, both C max and AUC 24 values over the range of 30 to 100 mg suggested a slightly greater than dose-proportional increase in exposure to ONO-2952. Repeat dosing of ONO-2952 indicated that the elimination rate of ONO-2952 was independent of dose and the apparent t ½ of ONO-2952 ranged from 37 to 42 hours. The accumulation ratios observed were comparable across the doses tested (30, 60, and 100 mg) and concentrations of ONO-2952 in the plasma reached steady state by Day 10, as expected considering the pharmacokinetic profile following a single dose. These safety and pharmacokinetic data combined provide the basis for exploration of ONO-2952, a novel and selective TSPO antagonist, in further clinical studies.
Modifying the activity of TSPO may have implications for pharmacologic intervention in many diseases. Increased TSPO expression is associated with the inflammatory response, cellular repair, and cell survival. 15 Inhibition of TSPO activity can induce apoptosis in various tumor cell types, [16] [17] [18] whereas high levels of TSPO expression are associated with the most aggressive forms of cancer. 19 However, inhibition of TSPO can also restore myocardial function in cardiovascular disorders and prevent apoptosis in myocardial infarction. [20] [21] [22] These studies highlight that the role of TSPO in cell survival is complex and targeting TSPO function may be beneficial in several pathologies. Regulation of TSPO has demonstrated efficacy in several centrally mediated disease models. In rodents, TSPO agonists can decrease neuron cell death and reduce the inflammatory response following induced brain lesions, 23, 24 exert antidepressant and anxiolytic effects in stress models, 25, 26 and promote analgesia in inflammatory pain. 27 Similarly, the novel TSPO antagonist ONO-2952 reduces visceral hyperalgesia, defecation, and freezing behavior in stress-induced rats. 13 These studies suggest that TSPO antagonism may also be a plausible approach to regulate TSPO. The ability of ONO-2952 to inhibit noradrenalin release in the amygdala with a similar efficacy to diazepam in a rat restraint stress model 13 supports the notion that ONO-2952 may be efficacious in a broad range of stress-related disorders such as anxiety and depression. following multiple oral administration to healthy subjects in the multiple ascending dose study (n ¼ 8-9) (Pharmacokinetic Evaluable Set). 
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